The Motley Fool

2 ‘evergreen’ Neil Woodford picks I’d buy now

When Neil Woodford started his own fund management business he began by launching the CF Woodford Equity Income Fund with the aim of investing in quality companies with sustainable dividend growth.

The firm’s website tells us that Woodford expects to achieve capital growth and a growing income stream for investors by investing over the long term.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Getting the big calls largely right

Mr Woodford has earned a reputation for getting the big calls largely correct and thus doing a lot to protect his fund investors’ capital, such as avoiding the big banks before the financial crisis and keeping away from them ever since. He also turned his back on those traditional high dividend payers the utility firms when he thought regulatory risk was too high.

Since the Equity Income fund’s launch in June 2014, the total return stands at just over 31%, which continues a decades-long run of success for Mr Woodford. Given his impressive long-term investment record, I reckon it’s a good idea to consider the shares he seems most keen about, and by weighting, number one and number three in the CF Woodford Equity Income Fund are pharmaceuticals giant AstraZeneca (LSE: AZN) and tobacco products firm Imperial Brands (LSE: IMB).

Despite many other FTSE 100 firms getting the chop from the fund recently, these two account for more than 16% of funds invested. I think it could be safe to assume he really likes them (still). So why might that be?

Defensive characteristics

The Woodford website says that: Investors expect a positive return and that is what we aim to deliver over the long term – protecting capital is key.” This emphasis on avoiding losses as a key step to realising gains chimes with the advice we receive from other well-known investors such as Warren Buffett and Peter Lynch.

AstraZeneca and Imperial Brands strike me as good vehicles to help investors avoid losses because of their defensive characteristics. Both firms deal in short-life consumable goods that people buy over and over again. Medicines and tobacco products are among the most ‘sticky’ of all such consumables, people rarely forgo them no matter how tough economic times become.

That’s the essence of defensiveness because it leads to reliable cash inflow for a firm, which enables a strong dividend. From such a base, any growth at all is the icing on the cake.

Valuation

It’s one thing finding a firm with a defensive business, but such attractive qualities often come at a price, expressed in a high valuation.

Yet at 4,605p, AstraZeneca’s forward price-to-earnings (P/E) ratio runs around 14.5 for 2018 and the forward dividend yield is just under 4.9%. Meanwhile, at 3,762p, Imperial Brands’ forward P/E for the year to September 2018 is just over 13 and the forward dividend yield is running just above 5%.

These are not wild over-valuations, in fact, they look modest and must add to the attraction that Neil Woodford sees. I reckon these two evergreen defensive stalwarts are a good place to start if you are building your own defensive portfolio and I would buy them right now.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Imperial Brands. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.